Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
Type:
Grant
Filed:
January 2, 1998
Date of Patent:
August 27, 2002
Assignee:
GSF-Forschungszentrum fur Umwelt und Gesenudheit GmbH
Inventors:
Gerd Sutter, Marion Ohlmann, Volker Erfle